CPHI April 19-21 TOKYO: IBSA returns to Japan after the pandemic.

IBSA operates in more than 90 countries and 5 continents with 17 subsidiaries in Europe, China and the USA, and employs over 2,000 collaborators distributed among our headquarters, subsidiaries and manufacturing plants.

The Group boasts an extensive product portfolio that includes different therapeutic categories, such as prescription drugs, OTC medicines, medical devices and food supplements, and covers 10 therapeutic areas. The company holds 90 patent families and several others in the pipeline.

Over the years IBSA’s Researchers have developed innovative technologies, novel formulations and delivery systems such as softgel capsules, orodispersible films, pre-filled syringes, patches (hydrogel and drug-in-adhesive technologies), gonadotropins purification process, progesterone & ßciclodestrine, single dose strip, nahyco hybrid technology, device for intravesical infusion.

At CPHI Japan IBSA will present some of its most innovative products and formulations, such as:

  • Sinovial – Efficacy and tolerability of Sinovial® is demonstrated in the treatment of knee OA and many musculoskeletal conditions (hip OA, painful shoulder, hand OA, trigger finger, foot OA, TMJ). Efficacy already evident starts from the first injection and lasts up to 6 months, suggesting a long-lasting carry-over effect of the treatment.
  • Sinogel – Sinogel® is indicated for pains or reduced joints mobility due to degenerative diseases, post-traumatic diseases or joint and tendon alterations. It substitutes the synovial fluid and allows the re-establishment of the physiological and rheological properties of joints affected by arthrosis.
  • Prolutex – Prolutex® is indicated in adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.
  • Ialuril Prefill – Ialuril® Prefill is indicated to re-establish the glycosaminoglycan layers (GAGs) of the urothelial vesical tissue in cases their loss can cause frequent and recurring problems (such as, for example, cystitis of varying etiology).
    Ialuril® Prefill is also indicated in the cases where the loss of the glycosaminoglycan layer is associated with forms of chronic inflammation, in which their composition and integrity appears compromised in different ways.

Oro-dispersible Film
IBSA Iron – Iron is an essential mineral that plays a crucial role in human growth and development. This new formulation gives more oxygen and energy to the body.

Vitamin D3 – When skin irradiation is insufficient to produce the required amount of biologically active vitamin D3, an exogenous intake is needed to prevent skeletal mineralization defects.

Thanks to its consolidated experience, its industrial capacity and its proprietary technologies, IBSA is the ideal partner to serve other companies in the pharmaceutical and nutraceutical industry, providing strategic licensing agreements, in countries where it does not operate directly with its branches, and comprehensive services from drug development through drug manufacturing for EU and non-EU markets.

Related Articles
ARTROSIS Y VISCOSUPLEMENTACIÓN – Publirreportaje – Chemistry Today
Artrosis, la causa más frecuente de discapacidad musculoesquelética. Descubramos más con la TECNOLOGÍA HÍBRIDA NAHYCO® de IBSA.
Osteoarthritis, the most common cause of musculoskeletal disability. Let’s find out more with the IBSA NAHYCO® HYBRID TECHNOLOGY.
Unas palabras con Andrea Taborelli – Entrevista con Chimica Oggi – Chemistry Today
Andrea Toborelli, Director de Desarrollo Empresarial y Licencias de IBSA, fue entrevistado por Nutra Horizons. 
We’re looking for partners and international distributors for our products.



Via del Piano 29,
6926 Collina d’Oro,
Tel. +41 58 360 10 00




Follow us